title: Gene expression analyses implicate an alternative splicing program in regulating contractile gene expression and serum response factor activity in mice.
abstract: Members of the CUG-BP, Elav-like family (CELF) regulate alternative splicing in the heart. In MHC-CELFΔ transgenic mice, CELF splicing activity is inhibited postnatally in heart muscle via expression of a nuclear dominant negative CELF protein under an α-myosin heavy chain promoter. MHC-CELFΔ mice develop dilated cardiomyopathy characterized by alternative splicing defects, enlarged hearts, and severe contractile dysfunction. In this study, gene expression profiles in the hearts of wild type, high- and low-expressing lines of MHC-CELFΔ mice were compared using microarrays. Gene ontology and pathway analyses identified contraction and calcium signaling as the most affected processes. Network analysis revealed that the serum response factor (SRF) network is highly affected. Downstream targets of SRF were up-regulated in MHC-CELFΔ mice compared to the wild type, suggesting an increase in SRF activity. Although SRF levels remained unchanged, known inhibitors of SRF activity were down-regulated. Conversely, we found that these inhibitors are up-regulated and downstream SRF targets are down-regulated in the hearts of MCKCUG-BP1 mice, which mildly over-express CELF1 in heart and skeletal muscle. This suggests that changes in SRF activity are a consequence of changes in CELF-mediated regulation rather than a secondary result of compensatory pathways in heart failure. In MHC-CELFΔ males, where the phenotype is only partially penetrant, both alternative splicing changes and down-regulation of inhibitors of SRF correlate with the development of cardiomyopathy. Together, these results strongly support a role for CELF-mediated alternative splicing in the regulation of contractile gene expression, achieved in part through modulating the activity of SRF, a key cardiac transcription factor.
authors: Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
authors: Twishasri
authors: T
authors: Dasgupta
authors: Samantha J
authors: SJ
authors: Stillwagon
authors: Andrea N
authors: AN
authors: Ladd
mesh_terms: D017398:Alternative Splicing / Q000235:genetics*; D000818:Animals; D051743:CCAAT-Enhancer-Binding Protein-delta / Q000235:genetics* / Q000378:metabolism; D020013:Calcium Signaling / Q000235:genetics / Q000502:physiology; D005786:Gene Expression Regulation; D008285:Major Histocompatibility Complex / Q000235:genetics; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009200:Myocardial Contraction / Q000235:genetics*; D009206:Myocardium / Q000378:metabolism; D026362:Serum Response Factor / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D024723:Ventricular Myosins
chemical_list: C497253:Cebpd protein, mouse; D026362:Serum Response Factor; D051743:CCAAT-Enhancer-Binding Protein-delta; D024723:Ventricular Myosins